Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lonafarnib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA known ✓ | P49354 | 20/20 | 1.00 |
| ▸ | FNTB known ✓ | P49356 | 20/20 | 1.00 |
| ▸ | HRAS | P01112 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lonafarnib SCHEMBL21630385 | 1.00 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| Lonafarnib SCHEMBL94653 | 1.00 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| Lonafarnib SCHEMBL29517258 | 1.00 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL13578722 | 0.93 | FNTA (0.88) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL6956843 | 0.93 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL17547678 | 0.92 | FNTA (0.86) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL31510741 | 0.92 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL12022170 | 0.92 | FNTA (0.85) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL13524750 | 0.92 | FNTA (0.85) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL14148187 | 0.92 | FNTA (0.85) | FNTAFNTBHRASKRASABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13494 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106552-A1 | THERAPEUTIC CONVERSION OF CANCER CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-05-21 | — | — | WO | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| US-12630593-B2 | Method of killing leukemia cells by administration of recombinant'Y3 proteins | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-19 | — | — | US | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| WO-2026090321-A1 | TREATMENT OF CANCER WITH A KRAS INHIBITOR | ALTEROME THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12605383-B2 | Methods of treating cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-04-21 | — | — | US | claimed |
| EP-4719410-A1 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF KRAS-DEPENDENT CANCERS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12576075-B2 | Combination therapies for treating cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | claimed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| US-20040106624-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME LLC | 2004-06-03 | — | — | US | claimed |
| US-20040102452-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2004-05-27 | — | — | US | claimed |
| US-20040102451-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2004-05-27 | — | — | US | claimed |
| US-20040097516-A1 | Novel pyrazolopyridines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2004-05-20 | — | — | US | claimed |
| WO-2004026872-A1 | PYRAZOLOPYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| WO-2004026229-A2 | PYRAZOLO[1,5-A]PYRIMIDINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| WO-2004022062-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2004-03-18 | — | — | WO | claimed |
| WO-2004022559-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2004-03-18 | — | — | WO | claimed |